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Introduction
Women who are carrying a trisomy 13 fetus are prone
to have an abnormal placenta as well as to develop
preeclampsia in the second and third trimesters. This
article provides a comprehensive review of the placen-
tal abnormalities, such as small placental volume, 
reduced placental vascularization, a partial molar
appearance of the placenta and placental mesenchy-
mal dysplasia, and preeclampsia associated with tri-
somy 13 pregnancies.
Placental Abnormalities Associated with
Trisomy 13 Pregnancies
Placental abnormalities associated with trisomy 13
include small placental volume, reduced placental vas-
cularization, a partial molar appearance, and placen-
tal mesenchymal dysplasia.
Small placental volume
Small placentas with reduced placental vascularization
have been associated with trisomy 13. In a pathologic
analysis of trisomy 21 (16 fetuses), trisomy 18 (25
fetuses) and trisomy 13 (seven fetuses), Arizawa and
Nakayama [1] found a tendency for heavy placentas in
trisomy 21 and a tendency for light placentas in trisomy
18 and trisomy 13, when compared with the standard
weight. They also found that human placentas in the
presence of trisomies 13, 18 and 21 had immature 
or dysmature villi. Placentas in pregnancies with tri-
somies 13, 18 and 21 have been shown to have different
lesions of hypotrophy, immaturity, hydrops, trophoblas-
tic cysts and mineralization of the trophoblastic basal
lamina [2]. In a study that compared first-trimester pla-
cental volume in 17 chromosomally abnormal preg-
nancies (nine cases of trisomy 21, four of trisomy 18,
two of trisomy 13, and one each of Turner syndrome
and 48,XXY,+21) and 2,846 normal pregnancies,
Metzenbauer et al [3] found that the placental volume
in the chromosomally abnormal group was significantly
lower than that in the normal cases. In a study that
measured placental volume using three-dimensional
ultrasound in 500 consecutive singleton pregnancies
(417 cases of normal karyotypes, 45 of trisomy 21, 17
of trisomy 18, 10 of Turner syndrome, and six of tri-
somy 13) immediately before chorionic villus sampling
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for fetal karyotyping at 11–13+6 gestational weeks (me-
dian, 12 weeks), Wegrzyn et al [4] found that in trisomies
13 and 18, the mean placental volume was significantly
smaller than that of the normal cases, and the volume
was below the 5th centile of the normal range in 39% of
cases. However, in trisomy 21 and Turner syndrome, the
mean placental volume was not significantly different
from that of the normal pregnancies.
Reduced placental vascularization
Feinberg et al [5] reported a pregnant multipara who
presented with severe preeclampsia, fetal trisomy 13,
the histopathologic findings of abnormal trophoblas-
tic invasion into the uterine spiral arteries with inade-
quate trophoblastic remodeling of the maternal uterine
vasculature and an absence of normal physiologic
changes in the spiral arteries. In a study of 25 chromo-
somally abnormal early ongoing pregnancies present-
ing with fetal aneuploidy (10 cases of trisomy 21, nine
of trisomy 18, three of triploidy, two of monosomy X
and one of trisomy 13) and 25 controls of chromo-
somally normal pregnancies, Jauniaux and Hustin [6]
found that the placentas of the aneuploid group was
systemically associated with trophoblastic hypoplasia,
stromal edema or cavitation, reduced vascularization
and ramification of the main villous trunks. In a study
of placental vascularization using three-dimensional
power Doppler ultrasound at 11–13+6 gestational weeks
in 100 normal control pregnancies and 25 aneuploid
pregnancies (13 cases of trisomy 21, eight of trisomy 18,
two of trisomy 13, one of triploidy and one of Turner
syndrome), Rizzo et al [7] found that the flow indices
were significantly reduced in cases with trisomies 13 and
18 compared with normal cases. However, the flow
indices in cases with trisomy 21 were not significantly
different from normal cases.
A partial molar appearance of the placenta
Partial moles have been well known to be associated
with diandric triploidy. Partial molar appearance has
been reported to present on prenatal ultrasound asso-
ciated with fetal trisomy 13. Jauniaux et al [8] first 
reported the diagnosis of partial mole in a pregnancy
with trisomy 13 at 21 gestational weeks and thought
that the villous edema was more likely related to insuf-
ficient development of the villous vasculature in some
placental areas. In that case, the villous trophoblasts
were microscopically normal, and the maternal serum
human chorionic gonadotropin (hCG) level was within
the normal range during pregnancy and follow-up after
delivery. Curtin et al [9] reported a case of trisomy 13
associated with preeclampsia and abnormal ultrasound
mimicking a triploid partial mole. Histologic examination
of the placenta in that case showed villous hydrops but
no evidence of trophoblastic hyperplasia. Has et al [10]
reported three cases of trisomy 13 with partial molar
appearance of the placenta in the second trimester. The
placentas had poor vascularization and focal villous
edema but no trophoblastic hyperplasia. The total hCG
levels were normal during and after the pregnancies.
Placental mesenchymal dysplasia
Placental mesenchymal dysplasia is characterized by
an enlarged hydropic placenta with multiple cysts and
dilated chorionic vessels, histologic features of enlarged
stem villi with loose connective tissue and cistern forma-
tion, and lack of trophoblastic proliferation and stromal
trophoblastic inclusions [11–15]. Placental mesenchy-
mal dysplasia may present the sonographic finding of
multiple cystic areas within the placenta, a normal or
slightly increased level of maternal serum β-hCG, an
elevated level of maternal serum α-fetoprotein and a
diploid fetus [11,12]. Placental mesenchymal dysplasia
has been a prominent prenatal sonographic feature of
Beckwith-Wiedemann syndrome owing to overproduc-
tion of IGF-2 [13]. Placental mesenchymal dysplasia
may be associated with chromosomal abnormalities
such as trisomy 13, Klinefelter syndrome, triploidy and
Xp deletion [13,16,17]. In a review of 66 cases with
mesenchymal dysplasia, Cohen et al [13] reported that
approximately one quarter of the cases had Beckwith-
Wiedemann syndrome, and among 36 cases karyotyped,
four (11%) had chromosomal abnormalities including
47,XY,t(1;13)(q32;q32),+13, 47,XXY, 69,XXX, and
46,XXp−. Cohen et al [13] found oligohydramnios,
intrauterine growth restriction, a cystic hygroma, con-
genital heart defects, and a normal postnatal maternal
serum β-hCG level a few weeks after delivery in the case
of trisomy 13. Müngen et al [17] reported a case of tri-
somy 13 with the karyotype 46,XY,der(13)t(13;13)
(q11;q11)[20]/47,XY,+13[11], normal levels of mater-
nal serum α-fetoprotein, hCG and unconjugated estriol,
multiple hypoechoic lesions throughout the entire pla-
centa, and a malformed fetus with postaxial polydactyly
of the hands and an atrial septal defect. The histopatho-
logic finding of the placenta was consistent with pla-
cental mesenchymal dysplasia.
Preeclampsia Associated with Trisomy 
13 Pregnancies
Bower et al [18] found that the incidence of trisomy 13
was 2.3 of 10,000 births in pregnancies with preeclamp-
sia in comparison with 0.5 of 10,000 births in preg-
nancies without preeclampsia. Evers et al [19] first
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reported severe toxemia and polyhydramnios in a case
with possible trisomy 13. Since then, numerous case
studies of preeclampsia with trisomy 13 have been re-
ported [5,18,20–25]. Boyd et al [20] studied 14 women
who gave birth to trisomy 13 infants and matched them
for age and parity to 28 normal controls, and found
that there was a significant increase in the incidence of
preeclampsia in the trisomy 13 group (5/14) compared
with the controls (0/28). Thornton et al [21] reported
that preeclampsia occurred in two out of five multi-
parous women who gave birth to trisomy 13 infants.
Bower et al [18] reported that preeclampsia occurred in
two out of nine cases of trisomy 13. Touhy and James
[22] studied 25 women who gave birth to trisomy 13
infants and matched them for age, parity and date of
delivery to 50 normal controls, and found that there
was a significantly increase in the incidence of preeclamp-
sia in the trisomy 13 group (6/25) compared with the
controls (1/50).
Extra Copy of Candidate Preeclampsia-
causing Genes on Chromosome 13
Reported candidate preeclampsia-causing genes on
chromosome 13 include sFlt1, COL4A2 and periostin.
sFlt1
sFlt1 maps to 13q12 and encodes the placental soluble
FMS-like tyrosine kinase 1 (sFlt1), which binds vascular
endothelial growth factor (VEGF) with high affinity. sFlt1
is a splice variant of the VEGF receptor Flt1, lacking the
transmembrane and cytoplasmic domains. FMS-like
tyrosine kinase 1 (Flt1) (OMIM 165070), also known as
vascular endothelial growth factor receptor 1 (VEGFR1),
has an extracellular region with seven immunoglobulin
(Ig)-like loops containing a ligand binding domain and
a dimerization domain in the N-terminal, a transmem-
brane domain region, and a split tyrosine kinase domain
[26]. Kinase insert domain receptor (KDR) (OMIM
191306), also known as vascular endothelial growth
factor receptor 2 (VEGFR2), has an extracellular region
with seven Ig-like loops in the N-terminal, a transmem-
brane domain region, and a split tyrosine kinase domain
[26]. sFlt1 is a splicing Flt1 variant that is truncated at
the C-terminus. sFlt1 has only six Ig-like loops and addi-
tional 31 amino acid stretch which is encoded in the 
5-region of intron 13. sFlt1 acts as a potent VEGF and
placental growth factor (PGF) antagonist [26,27]. VEGF
(OMIM 192240) and PGF (OMIM 601121) belong 
to the VEGF family, which is essential for angiogenesis,
the maintenance of endothelial cell status, and vessel
wall permeability [28]. VEGF exerts biologic effects by
binding the receptor Flt1 or KDR, and PGF exerts bio-
logic effects by binding the receptor Flt1. sFlt1 binds
VEGF and PGF, and thus prevents VEGF and PGF from
interacting with Flt1 and KDR [26,27].
In animal models, infusion of sFlt1 induces manifes-
tation of preeclampsia [29]. Placental sFlt1 expression
has been noted to be elevated in preeclampsia [30]. 
By using Affymetrix U95A microarray chips (Affymetrix,
Inc., Santa Clara, CA, USA), Maynard et al [29] per-
formed gene expression profiling of placental tissue from
women with or without preeclampsia and found that
sFlt1 mRNA was upregulated in the preeclamptic pla-
centas, leading to increased systemic levels of sFlt1.
Vuorela et al [31] found that sFlt1 levels in the amniotic
fluid were elevated in preeclampsia. Maynard et al [29]
also found that increased circulating sFlt1 in patients
with preeclampsia was associated with decreased circu-
lating levels of free VEGF and PGF. Many other studies
have confirmed that alterations in circulating angio-
genic factors play an important role in the pathogene-
sis of preeclampsia [32–46]. Bdolah et al [25] found
that trisomy 13 pregnancies had increased circulating
sFlt1/PGF ratios compared with trisomy 18 or trisomy
21 pregnancies, or normal karyotype pregnancies, and
suggested that the increased risk of preeclampsia in
pregnant women with a trisomy 13 fetus may be directly
related to the alterations in the angiogenic profile.
Wikström et al [43] reported that both early-onset and
late-onset preeclampsia were associated with altered
plasma levels of sFlt1 and PGF, and the alterations were
more pronounced in early-onset preeclampsia. Moore
Simas et al [44] found that maternal serum sFlt1 and
sFlt1/PGF ratio were altered prior to preeclampsia onset,
and suggested that serum sFlt1 and sFlt1/PGF ratio are
useful for the prediction of preeclampsia in high-risk
women. Baumann et al [45] found that both soluble
endoglin (sEng) and sFlt1 serum concentrations in the
first trimester were higher in women with subsequent
preeclampsia than in controls, and suggested that sEng
and sFlt1 are useful first-trimester serum markers to
predict preeclampsia. sFlt1-14, a natural VEGF inhibitor,
is a human-specific splice variant of Flt1 that contains
75 amino acids not present in sFlt1 and misses 31
highly conserved amino acids present in sFlt1. sFlt1-14
has been found to be upregulated in syncytial knots of
the preeclampsia placenta, and it is the predominant
VEGF-inhibiting protein produced by the preeclamptic
placenta [46].
Preeclampsia, abnormal placentation and excess
placental production of sFlt1
Maternal syndrome of preeclampsia has been thought
to be secondary to abnormal placentation and excess
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production of sFlt1 [38]. The hypoxic placenta produces
sFlt1, and its overexpression leads to preeclampsia [28].
Increased maternal serum levels of circulating sFlt1 in
trisomy 13 pregnancies have been noted in women who
carry a trisomy 13 fetus and an abnormal placenta with
an extra copy of the placental sFlt1 gene [25]. Decreased
uteroplacental blood flows, placental insufficiency and
placental hypoxia are associated with preeclampsia
[47–52]. Placental ischemia and hypoxia have also been
noted to induce excess sFlt1 production in preeclamp-
sia [53]. An interesting example that elevated levels of
sFlt1 may be triggered by various forms of placental
pathology is the case report of elevated sFlt1 level and
parvovirus-induced hydrops presented by Stepan and
Faber [54]. In that case, ultrasonography at 24 gesta-
tional weeks revealed a hydropic placenta and general-
ized fetus hydrops; cordocentesis confirmed severe fetal
anemia and parvovirus B19 infection, and the mother
had elevated serum levels of sFlt1 and preeclampsia.
However, with resolution of hydrops after intrauterine
blood transfusion, the sFlt1 level fell and the signs of
preeclampsia resolved.
COL4A2
COL4A1 (OMIM 120130) maps to 13q34 and encodes
the basement membrane α1 chain of type IV collagen
[55]. COL4A2 (OMIM 120090) maps to 13q34 and
encodes the basement membrane α2 chain of type IV
collagen [55,56]. Type IV collagen is associated with
laminin, entactin and heparan sulfate proteoglycans to
form the basement membranes that separate epithe-
lium from connective tissues. Bjørn et al [57] found that
type IV collagen messenger RNAs were highly expressed
and co-localized in the extravillous cytotrophoblasts 
of anchoring villi, in cytotrophoblasts that had pene-
trated into the placental bed, and in cytotrophoblastic
cell islands. Pang and Xing [58] demonstrated greater
than two-fold higher expression of 18 extracellular
matrix molecular genes including the COL4A2 gene in
preeclamptic placenta, and suggested that the abnor-
mal expression profiles of extracellular matrix molecules
might be associated with the pathogenesis of preeclamp-
sia. The abnormal expression of the collagen IV gene
may result in the ineffectiveness of basement membrane
remodeling and subsequent shallow trophoblastic infil-
tration [59]. In a heterogeneity-based genome search
meta-analysis for preeclampsia, Zintzaras et al [60]
identified a novel candidate chromosome region of
13q33.1–13q34 for general preeclampsia. Johnson et al
[59] have obtained strong evidence of linkage on 13q
with a peak logarithm-of-odds score of 3.10 between
D13S1265 and D13S173 (at about 123 cM), a critical
region where COL4A1 and COL4A2 reside. In a study
to detect maternal/fetal genotype incompatibility that
increases risk of preeclampsia, Parimi et al [61] found
that COL4A2 had a possible incompatibility effect.
Galewska et al [62] reported decreased activity of cathep-
sin D activity in the preeclampsia umbilical cord, leading
to reduced collagen degradation and subsequent accu-
mulation of collagen in the umbilical cord and uterine
arteries. The authors suggested that polymorphisms in
collagen that impact expression levels or degradation
by cathepsin D could influence the risk of developing
preeclampsia.
Periostin
Periostin or OSF2 (OMIM 608777) maps to 13q13.3
and encodes periostin or the osteoblast-specific factor
2 (OSF2), which has a sequence homology to insect
adhesion molecule fasciclin I and may play a role in
the adhesion process [63]. Sasaki et al [64] found that
serum periostin concentrations were elevated in pa-
tients with preeclampsia compared with normotensive
pregnant women, and that the periostin gene was
expressed in the stroma cells of placenta. The authors
suggested that human periostin may play a role in the
pathogenesis of preeclampsia, and that release of
adhesion molecule from the placenta could disturb
adhesion interaction between cells and regulate the
activation of leukocytes and endothelial cells, leading
to inflammation.
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